Emergent Biosolutions Stock Rating Upgraded by Zacks (EBS)
Emergent Biosolutions (NYSE:EBS) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Monday, American Banking & Market News reports. The firm currently has a $26.60 price objective on the stock. Zacks‘ target price would indicate a potential upside of 3.10% from the stock’s previous close.
Shares of Emergent Biosolutions (NYSE:EBS) traded up 3.49% during mid-day trading on Monday, hitting $25.80. 360,744 shares of the company’s stock traded hands. Emergent Biosolutions has a 1-year low of $13.02 and a 1-year high of $25.16. The stock’s 50-day moving average is $23.07 and its 200-day moving average is $19.46. The company has a market cap of $938.3 million and a P/E ratio of 28.07.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.37 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.21 by $0.16. The company had revenue of $89.10 million for the quarter, compared to the consensus estimate of $79.13 million. During the same quarter last year, the company posted $0.18 earnings per share. Emergent Biosolutions’s revenue was up 33.8% compared to the same quarter last year. On average, analysts predict that Emergent Biosolutions will post $0.80 earnings per share for the current fiscal year.
Emergent BioSolutions Inc is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.